Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.

Miguel MartinJ C de la Torre-MonteroS López-TarruellaK PinillaA CasadoS FernandezY JerezJ PuenteI PalomeroR González Del ValM Del Monte-MillanT MassarrahC VilaB García-ParedesJ A García-SáenzA Lluch

Published in: Breast cancer research and treatment (2018)

Adjuvant treatment with docetaxel (CD ≥ 400 mmg/m2) is associated with a significant rate of grade 2 PA, leading to wearing a wig, in around 10% of patients. This toxicity was completely prevented with scalp cooling. Clinical Trial Reference: NCT00515762.

Keyphrases

clinical trial
end stage renal disease
early stage
ejection fraction
chronic kidney disease
newly diagnosed
locally advanced
peritoneal dialysis
randomized controlled trial
young adults
open label
combination therapy
double blind
rectal cancer
nk cells
childhood cancer